The featured speakers will discuss the assessment of targeted LNP activity in cellular models, focusing on target engagement ...
Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target ...
Mirai advanced a CD8-targeted LNP from concept to functional non-human primate (NHP) proof-of-concept data in only 10 months, showing how its integrated platform can turn novel delivery designs into ...
Galmed Pharma announces breakthrough development of novel LNP cardiac targeted formulation of its SCD1 inhibitor, Aramchol: Ramat-Gan, Israel Friday, July 17, 2026, 17:00 Hrs [IST ...
AllerGene AI Therapeutics, a biotechnology company developing next-generation in vivo mRNA-LNP CAR-T therapies for mast ...
Oral presentation describes machine learning-guided multiparameter optimization of lipid nanoparticles (LNPs) to achieve selective delivery to adipose tissue Two poster presentations highlight Mirai’s ...
The approval of messenger RNA (mRNA) based COVID-19 vaccines marked a pivotal scientific milestone, establishing mRNA as an innovative drug modality with immense therapeutic potential. However, due to ...
Kunwoo Ryan Lee, PhD, knew as early as 2012 that solving the delivery problem would be crucial in fulfilling the promise of the newly discovered CRISPR-Cas9 gene editing technology. He felt strongly ...
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic and GI oncology diseases, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results